KRYS News

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

KRYS

(NASDAQ:KRYS) PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:20 am ET and host investor meetings throughout the day.

September 2, 2025Conference
Read more →

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

KRYS

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance following inhaled or intratumoral delivery to solid tumors.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

KRYS

May 26, 2025
Read more →

The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts

KRYS

May 16, 2025
Read more →

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

KRYS

May 9, 2025
Read more →

Guggenheim Maintains Buy on Krystal Biotech, Lowers Price Target to $189

KRYS

May 7, 2025
Read more →

Chardan Capital Maintains Buy on Krystal Biotech, Maintains $219 Price Target

KRYS

May 7, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $240 Price Target

KRYS

May 6, 2025
Read more →

Krystal Biotech Q1 EPS $1.20 Misses $1.32 Estimate, Sales $88.18M Miss $96.24M Estimate

KRYS

May 6, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $240

KRYS

April 29, 2025
Read more →

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

KRYS

April 28, 2025
Read more →

Demystifying Krystal Biotech: Insights From 7 Analyst Reviews

KRYS

April 28, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $240

KRYS

April 28, 2025
Read more →

EC Grants Marketing Authorization To Krystal Biotech's VYJUVEK For Treatment Of Wounds In Patients With DEB Who Have Mutations In COL7A1 Gene, Starting From Birth

KRYS

April 28, 2025
Read more →

Krystal Biotech Receives European Commission Approval Of VYJUVEK For The Treatment Of Dystrophic Epidermolysis Bullosa

KRYS

April 28, 2025
Read more →

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

KRYS

March 19, 2025
Read more →

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

KRYS

March 3, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

KRYS

February 28, 2025
Read more →

Krystal Biotech Secures Positive CHMP Opinion For VYJUVEK For Treatment Of Dystrophic Epidermolysis Bullosa

KRYS

February 28, 2025
Read more →

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

KRYS

February 24, 2025
Read more →

A Glimpse Into The Expert Outlook On Krystal Biotech Through 9 Analysts

KRYS

February 20, 2025
Read more →

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $215

KRYS

February 20, 2025
Read more →

Cantor Fitzgerald Reiterates Overweight on Krystal Biotech, Announces $215 Price Target

KRYS

February 20, 2025
Read more →

Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $218

KRYS

February 20, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

KRYS

February 19, 2025
Read more →

Krystal Biotech Q4 2024 GAAP EPS $1.52 Beats $1.16 Estimate, Sales $91.14M Beat $90.49M Estimate

KRYS

February 19, 2025
Read more →

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $206

KRYS

November 5, 2024
Read more →

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

KRYS

November 5, 2024
Read more →

Krystal Biotech Q3 2024 GAAP EPS $0.91 Beats $0.89 Estimate, Sales $83.84M Beat $82.95M Estimate

KRYS

November 4, 2024
Read more →